2 results
Approved WMORecruiting
Primary objective: to determine the biological activityof Hespecta that is able to induce HPV16 E6-specific T-cell immunity within a proposed dose escalation of 1, 5, 20 or 50 µg/peptide - conjugate in patients treated for HPV16+ OSCC.Secondary…
Approved WMOCompleted
to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.